Announcement of Availability for Cirtuvivint
June 30, 2025
The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using cirtuvivint (SM08502), a first-in-class selective oral inhibitor of CDC2-like kinases (CLKs) and dual specificity tyrosine phosphorylation-regulated kinases (DYRKs) being developed by CTEP as an anticancer agent in collaboration with Biosplice Therapeutics. CTEP will also consider requests to supply cirtuvivint for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).
All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.
If you are a HCC Investigator interested in submitting an LOI using cirtuvivint through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).
Questions may be addressed to Dr. Steven D. Gore (steven.gore@nih.gov) Medical Officer, Investigational Drug Branch, CTEP. please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).